As of Q4'25, Eli Lilly (LLY) reported its highest quarterly operating income in the period, reaching USD 8.78B. This represents a significant year-over-year growth rate of 74.16%, highlighting a strong finish to the year. From Q1'23 to Q4'25, LLY's operating income exhibited substantial volatility, with notable dips in Q3'23 (USD 427.2M) and Q3'24 (USD 1.59B), followed by sharp recoveries and robust growth, especially in the latter half of 2024 and throughout 2025. The year-over-year growth rates fluctuated widely, peaking at 355.33% in Q3'25, indicating periods of both contraction and rapid expansion. Overall, the trend demonstrates accelerating operational profitability, with particularly strong momentum in the most recent quarters.